Participants 24 65 4
safety in patients with advanced melanoma
Participants 322 375 5
in previously treated patients with advanced melanoma
Participants 470 517 3
enrolled patients without regard to HLA subtype
Participants 529 695 5
nrollment in the phase III trial was restricted to class-I HLA-A*0201-positive patients because two of the three arms contained an HLA-A*0201-restricted gp100 vaccine
Participants 697 808 4
HLA typing was also performed prospectively in several phase II trials and was available for 93.5% of patients.
Participants 900 1020 4
HLA-A*0201 status and dose from pretreated patients randomized to 0.3, 3, or 10 mg/kg ipilimumab in four phase II trials
Participants 1330 1410 3
137 HLA-A*0201-positive patients randomized to ipilimumab in the phase III study
